Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Histone deacetylase (HDAC) inhibitors show promise in cancer therapy, but pan-HDAC inhibitors cause adverse effects.
• Development of isotype-selective HDAC inhibitors is crucial to mitigate undesirable responses.
• Targeting specific HDAC isoforms, like HDAC6, may offer improved therapeutic profiles.

Purpose of the Study:

• To develop and validate a quantitative cellular assay using high-content analysis (HCA) for assessing HDAC6 and Class I HDAC isoform inhibition.
• To optimize critical assay parameters for robust and reproducible results.
• To screen compounds for HDAC6 selectivity and gather structure-activity relationship (SAR) data.

Main Methods:

• Utilized high-content analysis (HCA) for quantitative cellular assays.
• Detected substrate acetylation (α-tubulin for HDAC6, histone H3 for Class I HDACs) to measure enzyme activity.
• Validated assay conditions including cell seeding, fixation, permeabilization, and antibody dilutions.

Main Results:

• The HCA assay effectively quantified the inhibition of HDAC6 and Class I HDAC isoforms.
• Optimization and validation confirmed the assay's robustness for measuring compound selectivity.
• Screening of compounds provided valuable SAR information for selective HDAC6 inhibitors.

Conclusions:

• The developed HCA assay is a powerful and validated tool for screening selective HDAC6 inhibitors.
• This assay facilitates the identification of compounds with improved selectivity profiles.
• The HCA assay supports the development of targeted cancer therapies with potentially reduced side effects.